Revvity, Inc. RVTY announced the launch of the in-vitro diagnostic EURORealTime APOE assay in European countries that accept the CE mark on Oct. 2. The assay will likely enable accurate genotyping of ...

The two FDA-approved drugs have demonstrated in clinical trials the capability to slow cognitive decline by several months, The Washington Post reported Oct. 8.

We recently compiled a list of the 10 stocks that will make you rich in 5-10 years. In this article, we are going to take a ...

UTHealth Houston is the first institution in Houston to administer an FDA-approved drug, Kisunla (donanemab-azbt), for the ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 568.82% and ...

Kisunla is a 0nce-a-month, 30-minute infusion that is shown to slow the progression of the disease by 37 percent and reduce Alzheimer's-causing plaques by 84 percent.

Lilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer’s disease, ALS and other brain diseases, CEO David Ricks said.

From biochemist to executive supplier to angel investor to company founder and CEO, Maria Maccecchini, Ph.D.’s ...

Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies' research progress. Here’s a list of conferences to watch in 2025.

WASHINGTON, DC / ACCESSWIRE / October 1, 2024 / Boosting research investment into the health and wellbeing of adults with Down syndrome would ...

New blood tests could help doctors diagnose Alzheimer’s disease faster and more accurately, researchers reported in July. But ...

Eli Lilly & Co. Inc. said Tuesday the Japanese regulator has approved its Kisunla treatment for adults with early symptomatic Alzheimer’s disease, including those with mild cognitive impairment ...